12399456https://www.upal.com.my/zh/feeds/jobFeedKwongwahArray ( [0] => HTTP/1.1 200 OK [1] => Date: Mon, 02 Dec 2024 11:48:19 GMT [2] => Content-Type: text/xml; charset=utf-8 [3] => Connection: close [4] => Vary: Accept-Encoding [5] => X-Powered-By: PHP/7.4.33 [6] => Cache-Control: no-cache, private [7] => Set-Cookie: UpalLiveSession=eyJpdiI6IjhZMnNRSTdnZFdmQkJUWHNoaUhGZHc9PSIsInZhbHVlIjoieFpNUHc3Y3BMWHlFRk52azFydklLRU40a0k1QjAydE9HZU9Pd0UrTVF6RDBlOTE1WkNDQVdxRjRKUCtkKzJrNXBCMlF0TzlVZ0tFb2w4a2YzSWpDR2c9PSIsIm1hYyI6IjU5YjcyZTU5NGNlYzc0YzlhNmI2MTQ5YTM5NzZjZTk5ZTBlMmJjOWM1ZDU1NzA3Nzk3MjIwY2NmOTE3NmI0M2YifQ%3D%3D; expires=Thu, 02-Dec-2027 11:48:19 GMT; Max-Age=94608000; path=/; HttpOnly [8] => X-Frame-Options: SAMEORIGIN [9] => X-XSS-Protection: 1; mode=block [10] => X-Content-Type-Options: nosniff [11] => Referrer-Policy: no-referrer-when-downgrade [12] => CF-Cache-Status: DYNAMIC [13] => Report-To: {"endpoints":[{"url":"https:\/\/a.nel.cloudflare.com\/report\/v4?s=7jhLSzgXJq4g2jQAEa4dfgFGKglND7RsZfufLRegRMsZfxhIGgGWnodILgQHvaxDyuub0Cwcb7mNfEiXzllCSB6KvGqMgd5PDB94WVBefd5Fa9AqmZHRlXa5jjQUBW17kI0%3D"}],"group":"cf-nel","max_age":604800} [14] => NEL: {"success_fraction":0,"report_to":"cf-nel","max_age":604800} [15] => Server: cloudflare [16] => CF-RAY: 8ebb16509b0914e6-LAX [17] => alt-svc: h3=":443"; ma=86400 [18] => server-timing: cfL4;desc="?proto=TCP&rtt=197516&min_rtt=197469&rtt_var=55591&sent=5&recv=6&lost=0&retrans=0&sent_bytes=2998&recv_bytes=756&delivery_rate=14665&cwnd=33&unsent_bytes=0&cid=90ae9fc7e5f7ac2d&ts=1016&x=0" ) 789

美国于6日将用在研究的抗病毒药物瑞德西韦（Remdesivir），成功治愈新冠肺炎患者。

首批收治患者的武汉市金银潭医院，于周四启动美国新药的临床试验，为308名轻至中症患者、453名重症患者进行“双盲试验”，评估它的疗效和安全性。

该试验计划预计完成时间为今年4月27日，试验组和对照组在第1天分别给予瑞德西韦和安慰剂200毫克负荷剂量，然后每天一次100毫克静脉内维持剂量，持续9天。

试验专案负责人曹彬指出，由于瑞德西韦治疗的病例仅有1宗，加上其第1期、第2期安全性试验是在境外完成，与中国存在人种差异，故必须执行严格的随机双盲试验，患者与医生都不清楚所服用的究竟是试验药还是安慰剂，直至揭盲时才能确信药物效果。

---

// // // //